Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

TL;DR: Compared with chemotherapy alone, tislelizumab plus chemotherapy was cost-effective for the treatment of R/M NPC in China from the perspective of the Chinese healthcare system.

TL;DR: The introduction of immunotherapy into the care of patients with metastatic and recurrent cervical cancer, a disease with a historically poor prognosis and limited treatment options, has altered the standard of care as mentioned in this paper .

TL;DR: Wang et al. as mentioned in this paper reported a rare case of a patient with primary advanced vaginal carcinoma combined with cervical adenocarcinoma, based on a gynecological examination, colposcopy biopsy with histopathological examination and computed tomography scan.

Abstract: Background: Cervical cancer remains a major health problem, and HPV-independent subtypes such as gastric-type adenocarcinoma carry dismal outcomes. Although immune checkpoint inhibitors (ICIs) have improved survival in large trials, their real-world effectiveness including HPV-independent tumors is not well established. Methods: We conducted a retrospective multicenter study of two surrogate cohorts representing refractory cervical cancer: patients treated with bevacizumab (Bev-cohort, n=65) and those undergoing comprehensive genomic profiling (CGP-cohort, n=42). Early ICI administration was evaluated using landmark analysis (Bev: 180 days; CGP: 6 months), with differences in restricted mean survival time (ΔRMST) as the primary endpoint. Multivariable Cox models adjusting for stage, histology, and treatment interval were performed as secondary analyses. Exploratory analyses assessed HPV and molecular status for associations with ICI response. Results: In the Bev-cohort, 14 ICI-treated patients achieved significantly longer survival than 48 non-ICI patients (ΔRMST +19.4 days at 180 days; +56.2 days at 360 days). Multivariable Cox confirmed ICI as an independent predictor of survival (HR 0.15, 95%CI 0.01–0.69). In the CGP-cohort, 11 ICI-treated patients also experienced superior survival compared with 20 non-ICI patients (ΔRMST +1.05 months at 6 months; +2.33 months at 12 months). Among 36 ICI-treated cases overall, efficacy was not clearly associated with PD-L1 or tumor mutation burden status. Importantly, HPV-independent tumors, including gastric-type adenocarcinoma, demonstrated progression-free survival comparable to HPV-associated tumors. Conclusion: ICIs improved survival in advanced refractory cervical cancer across two real-world cohorts, with benefits observed irrespective of CPS/TMB status and extending to HPV-independent tumors.

TL;DR: The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials.

TL;DR: A 5-level version of the EQ-5D has been developed by the EuroQol Group and further testing is required to determine whether the new version improves sensitivity and reduces ceiling effects.

TL;DR: In this article, the authors proposed a more flexible method to construct discrete sequential boundaries based on the choice of a function, a*(t), which characterizes the rate at which the error level ac is spent.

TL;DR: The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival.